Moderna Launches New Venture Valera LLC for Infectious Diseases

Moderna Launches New Venture Valera LLC for Infectious Diseases

January 8, 2015

Moderna venture to advance mRNA vaccines and mRNA-based passive immunity therapies

CAMBRIDGE, Mass., Jan. 8, 2015— Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced the launch of Valera LLC, a new Moderna venture focused exclusively on the advancement of vaccines and therapeutics for the prevention and treatment of viral, bacterial and parasitic infectious diseases. 

Syros Pharmaceuticals to Present at the 33rd Annual J.P. Morgan 2015 Healthcare Conference

Syros Pharmaceuticals to Present at the 33rd Annual J.P. Morgan 2015 Healthcare Conference

January 7, 2015

Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, will present a corporate overview at the 33rd Annual J.P. Morgan Healthcare Conference, which takes place January 12 to 15, 2015, at the Westin St.

Symbiota Names Entrepreneurial Leader David P. Perry as President and CEO

Symbiota Names Entrepreneurial Leader David P. Perry as President and CEO

January 7, 2015

CAMBRIDGE, Mass., Jan. 7, 2015 /PRNewswire/ -- Symbiota™ announced today that David P. Perry has been named President and CEO to lead the company in its next phase of growth and commercialization. Symbiota is a pioneer of plant microbiome solutions that naturally promote crop health and improve agricultural production.

Onkaido Announces Appointment of Michael J. Morin, Ph.D., as Chief Scientific Officer

Onkaido Announces Appointment of Michael J. Morin, Ph.D., as Chief Scientific Officer

January 7, 2015

Former Pfizer research executive to lead scientific efforts in oncology drug development leveraging Moderna’s messenger RNA Therapeutics™ platform

Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin™ Platform for Cancer Therapeutics

Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin™ Platform for Cancer Therapeutics

January 7, 2015

WATERTOWN, Mass.--(BUSINESS WIRE)--Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding. The new financing includes additional equity investment from a new investor and all of Blend’s existing venture investors in an expansion of the Series B round, as well as debt financing from an institutional investment firm.

Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12

Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12

January 5, 2015

CAMBRIDGE, Mass.Jan.

Seres Health Announces $65 Million Investment from Nestlé Health Science

Seres Health Announces $65 Million Investment from Nestlé Health Science

January 6, 2015

CAMBRIDGE, Mass., January 6, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, announced today that it has completed a $65 million Series D preferred stock investment by Nestlé Health Science, a wholly-owned subsidiary of Nestlé.  Together with its recently announced $48 million Series C preferred stock financing, Seres Health had over $110 million of cash and investments at the end of 2014.

Moderna to Present at 33rd Annual J.P. Morgan Healthcare Conference

Moderna to Present at 33rd Annual J.P. Morgan Healthcare Conference

January 6, 2015

CAMBRIDGE, Mass., Jan. 6, 2015— Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that Stéphane Bancel, president and chief executive officer of Moderna, will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference.

Moderna Closes $450 Million Financing to Support Growth of Messenger RNA Therapeutics™ Platform across Diverse Therapeutic Areas

Moderna Closes $450 Million Financing to Support Growth of Messenger RNA Therapeutics™ Platform across Diverse Therapeutic Areas

January 5, 2015

CAMBRIDGE, Mass., January 5, 2015 - Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, announced today that it has raised $450 million in new funding to support the further expansion of its mRNA Therapeutics™ platform across multiple modalities and therapeutic areas. Since the company's founding in 2011 by Flagship VentureLabs™, Moderna has secured more than $950 million in funding through financing activities and commercial partnerships.

Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the field of Immuno-oncology

Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the field of Immuno-oncology

December 23, 2014

$3.2 Million Grant from Skolkovo Foundation for Novel Immunotherapeutic to Target Cervical, Head and Neck Cancers Associated with HPV